DNA Ginkgo Bioworks Holdings, Inc.

NYSE ginkgobioworks.com


$ 8.78 $ -0.56 (-6 %)    

Monday, 10-Nov-2025 19:58:43 EST
QQQ $ 623.82 $ 4.38 (0.71 %)
DIA $ 473.95 $ 1.94 (0.41 %)
SPY $ 681.69 $ 4.15 (0.61 %)
TLT $ 89.46 $ 0.06 (0.07 %)
GLD $ 380.15 $ 2.40 (0.64 %)
$ 8.77
$ 9.33
$ 8.70 x 20
$ 9.38 x 100
-- - --
$ 5.00 - $ 17.58
1,455,402
na
531.38M
$ 2.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-13-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-24-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ginkgo-bioworks-stock-plummets-following-q3-estimates-miss-reaffirms-fy2025-outlook-below-consensus

Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading lower on Friday. The company released its third-quarter financial re...

 ginkgo-bioworks-holdings-affirms-fy2025-sales-guidance-of-167000m-187000m-vs-177075m-est

Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$18...

 ginkgo-bioworks-holdings-q3-eps-145-misses-124-estimate-sales-38837m-miss-38850m-estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate ...

 ginkgo-bioworks-awarded-up-to-222m-contract-from-biopharmaceutical-manufacturing-preparedness-consortium-to-develop-innovations-to-lower-costs-of-local-biomanufacturing-of-monoclonal-antibodies

Ginkgo Bioworks (NYSE: DNA) announced today that it has been awarded a contract through the Biomedical Advanced Research and De...

 ginkgo-bioworks-extends-its-multi-year-partnership-with-bayer-to-continue-developing-biological-products-for-agriculture-focusing-on-microbial-nitrogen-fixation

Ginkgo Bioworks (NYSE:DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to adv...

 ginkgo-bioworks-collaborates-with-strmbio-and-university-of-british-columbia-to-develop-in-vivo-chimeric-antigen-receptor-therapies-for-autoimmune-diseases

Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo C...

 btig-maintains-sell-on-ginkgo-bioworks-holdings-raises-price-target-to-9

BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and raises the price target from $6 to $9.

 5-healthcare-stocks-on-fire-this-week

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech &...

 ginkgo-bioworks-announces-strategic-partnership-to-scale-ai-drug-discovery-via-datapoints-platform

Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that i...

 ginkgo-bioworks-holdings-q2-eps-110-beats-156-estimate-sales-5000m-beat-4161m-estimate

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of...

 ginkgo-bioworks-holdings-affirms-fy2025-sales-guidance-of-167000m-187000m-vs-178213m-est

Ginkgo Bioworks Holdings (NYSE:DNA) affirms FY2025 sales outlook from $167.000 million-$187.000 million to $167.000 million-$18...

 ginkgo-bioworks-to-build-automated-anaerobic-phenotyping-platform-for-emsl-using-reconfigurable-automation-cart-technology

Ginkgo will build a platform driven by its Reconfigurable Automation Carts (RACs) technology to enable EMSL's open-ended ex...

Core News & Articles

New terms provide Twist with key license to long DNA technology and assetsGinkgo to continue ordering from Twist with no purcha...

 ginkgo-bioworks-holdings-updates-fy2025-sales-guidance-from-16000m-18000m-to-16700m-18700m-vs-20201m-est

Ginkgo previously issued 2025 guidance for Total revenue of $160-$180 million, Cell Engineering revenue of $110-$130 million; a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION